The European Medicines Agency (EMA) has initiated a review of the weight management drug Mysimba following concerns regarding its potential long-term cardiovascular safety. 

What is Mysimba?

Mysimba is a weight loss medication consisting of 7.2 mg naltrexone and 78 mg bupropion as active substances. It is a prolonged release tablet ...